Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tide-A: avelumab plus intermittent axitinib in first-line metastatic renal cell carcinoma
2019-004098-23Phase 2Completed
- Sponsor
- Consorzio Oncotech
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axitinib and avelumab in metastatic renal cell carcinoma (mRCC), sponsored by Consorzio Oncotech. Primary endpoint: Progression-free status at week 8 after axitinib discontinuation. Started Jun 2021; status: completed.
02
Drugs
axitinibavelumab
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2019-004098-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004098-23.